Rigel Hit By Asthma Drug Failure

Rigel’s SKY inhibitor R343, intended to treat asthma, failed to meet both of its endpoints in a mid-stage clinical trial. The company’s stock dropped nearly 20 percent upon announcement of the unfavorable results.
Pharma Times